Pay in 4 interest-free payments of $5.59 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
Foviscu (WCK 4282) - Phase 3 Ongoing First-line empiric treatment for gram-negative hospital infections (cUTI, HABP/VABP) Complements ZAYNICH: while ZAYNICH is the destination therapy at the top of the pyramid for resistant infections, Foviscu is the entry-level, broad-use first drug of choice Global Phase 3 trial underway If approved, the commercial TAM is significantly larger than ZAYNICH due to broader use 5
By understanding these factors and the importance of consulting a healthcare professional, you can navigate the financial side of semaglutide treatment with more confidence
Talk with your prescribing physician to understand eligibility criteria, prior authorization requirements, and which specific medications are covered under the Bridge
[PubMed ID: 18825537]
No as seen on claims that cant be traced to actual coverage
US$ 22.05
US$ 24.69
US$ 26.73
US$ 25.80
